Donidalorsen: meta-analysis of COVID-19 studies

All studies Mortality Ventilation Serious outcomes RCTs RCT mortality Peer-reviewed All outcomes

Outcome (studies)

Improvement

Relative risk · 95% CI

All studies (1)−151%

Mortality (1)−151%

Ventilation (1)−81%

RCTs (1)−151%

Late (1)−151%

00.511.5+

← Donidalorsen
reduces riskIncreased
risk →

.hmva--anim-stagger .hmva__row{opacity:1}.hmva--anim .hmva__shade{opacity:var(--shade-opacity)}.hmva--anim-stagger .est .ci{transform:translateY(-50%)}.hmva--anim-stagger .est .pt{transform:translate(-50%,-50%)}.hmva--anim-stagger .hmva__bar{transform:none}.hmva--anim-settle .est .pt{left:calc(min(var(--pt), 1.5) / var(--max) * 100%)}.hmva--anim-settle .est .ci{left:calc(var(--lo) / var(--max) * 100%);width:calc((var(--hi) - var(--lo)) / var(--max) * 100%)}.hmva--anim-settle .hmva__bar--drug{width:calc(min(1, var(--rr)) * 100%)}.hmva--anim-settle .hmva__bar--control{width:calc(min(1, 1 / var(--rr)) * 100%)}

.fp--anim .fp__study,.fp--anim .fp__sum,.fp--anim .fp__het,.fp--anim .fp__dia,.fp--anim .fp__verdict,.fp--anim .fp__pooled{opacity:1}.fp--anim .fp__ci{transform:none}.fp--anim .fp__pt{transform:translate(-50%,-50%)}.fp--anim .fp__plot::before{opacity:var(--shade-opacity)}.fp--anim-settle .fp__pt{left:calc(min(var(--pt),var(--max))/var(--max)*100%)}.fp--anim-settle .fp__ci,.fp--anim-settle .fp__dia{left:calc(var(--lo)/var(--max)*100%);width:calc((var(--hi) - var(--lo))/var(--max)*100%)}

c19early.org

October 2026

Donidalorsen COVID-19 studies

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk

Zampieri (DB RCT)−151%2.51 · 0.89–7.02death12/526/51ASKCOV

Late treatment−151%2.51 · 1.02–6.1812/526/51151% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.045

All studies−151%2.51 · 1.02–6.1812/526/51151% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.04500.511.52+

Rotate screen for more detailsIncrease width for more details

← Donidalorsen
reduces riskDonidalorsen
increases risk →

c19early.org

October 2026

Donidalorsen COVID-19 mortality results

StudyImprovementRR · 95% CITreatmentControlRelative Risk

Zampieri (DB RCT)−151%2.51 · 0.89–7.0212/526/51ASKCOV

Late treatment−151%2.51 · 1.02–6.1812/526/51151% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.045

All studies−151%2.51 · 1.02–6.1812/526/51151% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.04500.511.52+

Rotate screen for more detailsIncrease width for more details

← Donidalorsen
reduces riskDonidalorsen
increases risk →

c19early.org

October 2026

Donidalorsen COVID-19 mechanical ventilation results

StudyImprovementRR · 95% CITreatmentControlRelative Risk

Zampieri (DB RCT)−81%1.81 · 0.84–3.1421/5610/55ASKCOV

Late treatment−81%1.81 · 0.94–3.4921/5610/5581% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.075

All studies−81%1.81 · 0.94–3.4921/5610/5581% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.07500.511.52+

Rotate screen for more detailsIncrease width for more details

← Donidalorsen
reduces riskDonidalorsen
increases risk →

c19early.org

October 2026

Donidalorsen COVID-19 serious outcomes

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk

Zampieri (DB RCT)−151%2.51 · 0.89–7.02death12/526/51ASKCOV

Late treatment−151%2.51 · 1.02–6.1812/526/51151% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.045

All studies−151%2.51 · 1.02–6.1812/526/51151% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.04500.511.52+

Rotate screen for more detailsIncrease width for more details

← Donidalorsen
reduces riskDonidalorsen
increases risk →

c19early.org

October 2026

Donidalorsen COVID-19 Randomized Controlled Trials

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk

Zampieri (DB RCT)−151%2.51 · 0.89–7.02death12/526/51ASKCOV

Late treatment−151%2.51 · 1.02–6.1812/526/51151% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.045

All studies−151%2.51 · 1.02–6.1812/526/51151% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.04500.511.52+

Rotate screen for more detailsIncrease width for more details

← Donidalorsen
reduces riskDonidalorsen
increases risk →

c19early.org

October 2026

Donidalorsen COVID-19 RCT mortality results

StudyImprovementRR · 95% CITreatmentControlRelative Risk

Zampieri (DB RCT)−151%2.51 · 0.89–7.0212/526/51ASKCOV

Late treatment−151%2.51 · 1.02–6.1812/526/51151% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.045

All studies−151%2.51 · 1.02–6.1812/526/51151% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.04500.511.52+

Rotate screen for more detailsIncrease width for more details

← Donidalorsen
reduces riskDonidalorsen
increases risk →

c19early.org

October 2026

Donidalorsen COVID-19 peer reviewed studies

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk

Zampieri (DB RCT)−151%2.51 · 0.89–7.02death12/526/51ASKCOV

Late treatment−151%2.51 · 1.02–6.1812/526/51151% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.045

All studies−151%2.51 · 1.02–6.1812/526/51151% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.04500.511.52+

Rotate screen for more detailsIncrease width for more details

← Donidalorsen
reduces riskDonidalorsen
increases risk →

c19early.org

October 2026

Donidalorsen COVID-19 outcomes

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk

Zampieri (DB RCT)−151%2.51 · 0.89–7.02death12/526/51ASKCOV Zampieri (DB RCT)−82%1.82 · 0.44–5.65death9/564/55ASKCOV Zampieri (DB RCT)−81%1.81 · 0.84–3.14ventilation21/5610/55ASKCOV Zampieri (DB RCT)−35%1.35 · 1.02–1.77progression56 (n)55 (n)ASKCOV

00.511.52+

Rotate screen for more detailsIncrease width for more details

← Donidalorsen
reduces riskDonidalorsen
increases risk →